Comparative Pharmacology
Head-to-head clinical analysis: VASOTEC versus ZESTORETIC.
Head-to-head clinical analysis: VASOTEC versus ZESTORETIC.
VASOTEC vs ZESTORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalaprilat, the active metabolite of enalapril, competitively inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and afterload.
Combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing diuresis and reducing plasma volume.
2.5 to 10 mg orally twice daily; initial dose 5 mg once daily; titrate based on blood pressure response; maximum 40 mg/day.
Zestoretic (lisinopril/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: 10 mg/12.5 mg, 20 mg/12.5 mg, or 20 mg/25 mg orally once daily. Maximum dose: lisinopril 80 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
Terminal half-life of enalaprilat is 35-38 hours, with multiple-dose half-life ~11 hours due to prolonged terminal phase; clinical context: once-daily dosing achieves steady-state in 3-4 days.
Lisinopril: terminal half-life approximately 12 hours (accumulation half-life 13.8 hours in patients with normal renal function). Hydrochlorothiazide: terminal half-life 5.6–14.8 hours (mean 9.6 hours).
Renal: 60-70% as enalaprilat; fecal: 20-30% as enalaprilat; biliary: minor (<10%).
Lisinopril is excreted unchanged in urine; 100% renal elimination. Hydrochlorothiazide is excreted primarily by the kidney (≥95% as unchanged drug) via tubular secretion.
Category C
Category C
ACE Inhibitor
ACE Inhibitor + Diuretic